六合彩开奖结果

SPEAKER:

Professor Roger Nitsch

Full Professor at the Faculty of Medicine, University of Zurich and Director at the Hospital for Psychogeriatric Medicine at the Psychiatric University Hospital Zurich.

听

TITLE:

鈥淒iscovery of Aducanumab for the treatment of Alzheimer鈥檚 disease鈥�

听

ALZHEIMER鈥橲 DISEASE is characterized by the deposition in brains of amyloid beta plaques and neurofibrillary tangles. Aggregation of amyloid beta in brain triggers a slowly progressing sequence of mildly synaptotoxic and neurotoxic activities, preceding the development of clinical dementia by more than 20 years. Cellular reactions to this chronic toxicity include synaptic dysfunction, tau pathology in neurons with the formation of neurofibrillary tangles and glial cell responses. Collectively, these pathogenic activities result in chronic neurodegeneration followed by progressive decline of global cognitive functions. As an initiator of this chronic cascade of degenerative activities, amyloid beta is a genetically validated target for drug development throughout industry. We have discovered, and licensed to Biogen, aducanumab, the first amyloid beta-removing antibody receiving accelerated approval by the U.S. FDA. Aducanumab removes brain amyloid beta in a dose- and time-dependent fashion, the biological basis for its FDA approval. Aducanumab is derived from human antibody-encoding memory-B cells. Clinical studies designed to confirm initial signs of clinical benefit are ongoing.